In the last trading session, 1.29 million shares of the Heron Therapeutics Inc (NASDAQ:HRTX) were traded, and its beta was 1.71. Most recently the company’s share price was $2.55, and it changed around -$0.16 or -5.90% from the last close, which brings the market valuation of the company to $383.34M. HRTX currently trades at a discount to its 52-week high of $3.22, offering almost -26.27% off that amount. The share price’s 52-week low was $0.50, which indicates that the current value has risen by an impressive 80.39% since then. We note from Heron Therapeutics Inc’s average daily trading volume that its 10-day average is 1.55 million shares, with the 3-month average coming to 3.05 million.
Heron Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 11 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended HRTX as a Hold, whereas 8 deemed it a Buy, and 0 rated it as Underweight. Heron Therapeutics Inc is expected to report earnings per share of -$0.09 for the current quarter.
Heron Therapeutics Inc (NASDAQ:HRTX) trade information
Instantly HRTX has showed a red trend with a performance of -5.90% at the end of last trading. The performance over the last five days has remained in the red territory. The company’s shares are currently up 50.00% year-to-date, but still down -13.56% over the last five days. On the other hand, Heron Therapeutics Inc (NASDAQ:HRTX) is -2.30% down in the 30-day period. We can see from the shorts that 25.43 million shares have been sold at a short interest cover period of 8.61 day(s).
The consensus price target as assigned by Wall Street analysts is $5, which translates to bulls needing to increase their stock price by 49.0% from its current value. Analyst projections state that HRTX is forecast to be at a low of $5 and a high of $5.
Heron Therapeutics Inc (HRTX) estimates and forecasts
Heron Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 147.57 percent over the past six months and at a 72.50% annual growth rate that is well above the industry average of 8.70%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 66.70% in revenue this quarter, and will report an increase of 80.00% in the next quarter. The year-over-year growth rate is expected to be 14.90%, up from the previous year.
Consensus estimates provided by 3 financial analysts predict the company will bring in an average of $32.8 million in revenue for the current quarter. 3 analysts expect Heron Therapeutics Inc to make $34.37 million in revenue for the quarter ending Jun 2024. The company’s sales for the same quarters a year ago were $29.61 million and $31.76 million respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 10.80%. Forecasts for the next quarter put sales growth at 8.20%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 20.01%. Heron Therapeutics Inc earnings are expected to increase by 73.33% in 2024, but the outlook is positive 47.50% per year for the next five years.
HRTX Dividends
Heron Therapeutics Inc’s next quarterly earnings report is expected to be released on March 12.
Heron Therapeutics Inc (NASDAQ:HRTX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.89% of Heron Therapeutics Inc shares, and 76.08% of them are in the hands of institutional investors. The stock currently has a share float of 76.77%. Heron Therapeutics Inc stock is held by 188 institutions, with Rubric Capital Management LP being the largest institutional investor. By Jun 29, 2023, it held 8.35% of the shares, which is about 11.75 million shares worth $13.63 million.
Blackrock Inc., with 5.95% or 8.38 million shares worth $9.72 million as of Jun 29, 2023, holds the second largest percentage of outstanding shares.
JP Morgan Small Cap Growth Fund and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Jun 29, 2023. The former held 3.95 million shares worth $4.58 million, making up 2.81% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 3.61 million shares worth around $4.18 million, which represents about 2.56% of the total shares outstanding.
